News

American Journal of Respiratory and Critical Care Medicine Publishes Landmark Data on AeroPace® System’s Breakthrough Results in Ventilator Weaning

International multi-center trial demonstrates AeroPace strengthens the diaphragm by 50%, weans more patients from ventilation, and reduces ventilator time by…

7 months ago

American Journal of Respiratory and Critical Care Medicine Publishes Landmark Data on AeroPace® System’s Breakthrough Results in Ventilator Weaning

International multi-center trial demonstrates AeroPace strengthens the diaphragm by 50%, weans more patients from ventilation, and reduces ventilator time by…

7 months ago

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

 – 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed…

7 months ago

Syndax Presents New Revuforj® (revumenib) Data in Relapsed/Refractory mNPM1 and NUP98r Acute Leukemia from AUGMENT-101 Trial at EHA 2025

 – 26% (20/77) CR+CRh rate and 48% (37/77) ORR in efficacy-evaluable pivotal R/R mNPM1 AML population – – Robust responses observed…

7 months ago

Catheter Precision (VTAK) Reports Key Progress for the LockeT Product

FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) --  Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device…

7 months ago

Catheter Precision (VTAK) Reports Key Progress for the LockeT Product

FORT MILL, S.C., June 12, 2025 (GLOBE NEWSWIRE) --  Catheter Precision, Inc. (VTAK - NYSE/American), a US based medical device…

7 months ago

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in…

7 months ago

BioNTech Announces Strategic Transaction to Acquire CureVac in Public Exchange Offer

Acquisition will strengthen the research, development, manufacturing and commercialization of mRNA-based cancer immunotherapy candidates, marking BioNTech’s next key milestone in…

7 months ago

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients

WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today…

7 months ago

New Prospective Cohort Study Reporting the Efficacy of Arrow™ Chlorhexidine-Impregnated Central Venous Catheters Demonstrates Reduced Infection Rates Among ICU Patients

WAYNE, Pa., June 12, 2025 (GLOBE NEWSWIRE) -- Teleflex Incorporated (NYSE: TFX), a leading global provider of medical technologies, today…

7 months ago